Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Arcellx, Inc. is a clinical-stage biotechnology company focused on developing cell-based immunotherapies for cancer, operating within the biopharmaceutical and cell therapy industries. The company’s core focus is the development of next-generation chimeric antigen receptor T-cell (CAR‑T) therapies using its proprietary D‑Domain protein platform, which is designed to improve stability, specificity, and manufacturability compared to traditional single-chain variable fragment (scFv) CAR constructs.
Arcellx’s primary value driver is its lead CAR‑T product candidate, anito-cel (also referred to in public disclosures as CART‑ddBCMA), which targets B‑cell maturation antigen (BCMA) for the treatment of multiple myeloma. The company primarily serves oncology patients through partnerships with large biopharmaceutical companies and clinical research networks. Founded in 2014, Arcellx evolved from early platform research into a clinically focused oncology company, advancing from preclinical development into mid-stage clinical trials and strategic collaborations.
Business Operations
Arcellx operates as a single-segment company focused on cell therapy research and development, generating no commercial product revenue as of the latest publicly available filings. Its operations center on internal discovery, preclinical validation, clinical development, and manufacturing process design for CAR‑T therapies. The company’s proprietary D‑Domain technology is a core asset and underpins all internal and partnered development programs.
The company conducts clinical development primarily in the United States, with manufacturing activities supported through a combination of internal capabilities and third-party contract manufacturing organizations. A major operational partnership is with Gilead Sciences, Inc., through its Kite Pharma subsidiary, which collaborates with Arcellx on the global development and potential commercialization of anito-cel. Arcellx operates as a standalone public company with no consolidated operating subsidiaries disclosed as material revenue-generating entities.
Strategic Position & Investments
Arcellx’s strategic direction centers on advancing anito-cel toward late-stage clinical development while leveraging its D‑Domain platform to generate additional oncology candidates. A key strategic milestone was the 2022 global strategic collaboration and co-development agreement with Kite Pharma, which included upfront payments, equity investment, and shared development costs, positioning Arcellx with extended financial runway and reduced commercialization risk.
Beyond its lead program, Arcellx continues to invest in pipeline expansion targeting additional hematologic malignancies and solid tumors, although detailed clinical-stage data for these earlier programs remains limited in public disclosures. The company does not report ownership of unrelated portfolio companies, instead focusing capital allocation on internal R&D and clinical execution. Data on additional acquisitions or equity investments beyond the Kite collaboration is inconclusive based on available public sources.
Geographic Footprint
Arcellx is headquartered in Gaithersburg, Maryland, and its operational footprint is primarily concentrated in North America. Clinical trials are conducted predominantly in the United States, leveraging domestic oncology research centers and trial networks. The company does not report significant standalone commercial operations outside the U.S.
International reach is primarily indirect and driven through its collaboration with Kite Pharma, which provides potential access to Europe and other global oncology markets pending regulatory approvals. Arcellx itself does not currently maintain material international offices or manufacturing sites disclosed in public filings.
Leadership & Governance
Arcellx is led by an executive team with experience in biotechnology, oncology drug development, and capital markets, emphasizing disciplined clinical execution and platform-driven innovation. The leadership’s stated strategic vision focuses on advancing differentiated CAR‑T therapies with improved safety, durability, and scalability.
Key executives include:
- Rami Elghandour – President & Chief Executive Officer
- Michael C. Wallace – Chief Financial Officer
- Andrew Pecora – Chief Medical Officer
- Robert C. Deignan – Chief Operating Officer
- Matthew DeFazio – Chief Legal Officer & Corporate Secretary
The board of directors includes biotechnology executives and investors with experience in clinical-stage company governance and strategic transactions, aligning oversight with long-term value creation through clinical and regulatory milestones.